# A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

> **NCT04049929** · PHASE1 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT04049929
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049929, "A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04049929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*